Hypertension Clinical Trials & Research Studies Near You (Updated 8/25)

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

NCT05331144

Recruiting

The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.

Gender:

ALL

Ages:

Between 60 years and 85 years

Trial Updated:

07/31/2025

Locations: University of Texas Southwestern Medical Center, Dallas, Texas

Conditions: Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia

Register for Updates

Learn More ›

Impact GLP-1 Agonists Following Bariatric

NCT06132477

Recruiting

Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control. Bariatric surgical procedures have been shown to be effective in treating obesity as w... Read More

Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control. Bariatric surgical procedures have been shown to be effective in treating obesity as well as superior to best medical therapy for treatment of diabetes not just through restriction of calories but also through a positive impact in modifications of gut hormones, changes in circulating bile acids, modifications in the gut microflora as well as other undefined mechanisms. The combined benefits of GLP1-RAs with bariatric surgery have only been studied to a limited effect. In this randomized trial, the effects of continuation or discontinuation of GLP1-RA therapy in patients undergoing bariatric surgery will be determined. We will compare changes in weight, metabolic determinants including circulating bile acids and gut microbiome, psychological determinants of eating behavior, and adverse side effects in patients who continue vs discontinue therapy. Given differences in metabolic and clinical outcomes in patients undergoing vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB), both surgical groups will be examined. The study will be conducted at a high volume bariatric surgical program where patients will undergo randomization at the time of final clinic visit prior to surgery to continue or discontinue GLP1-RA. It is hypothesized that participants who continue GLP1-RA therapy after bariatric surgery will lose more weight with improved blood glucose control than those who discontinue therapy. Furthermore, changes in gut microbiome and circulating bile acids, known determinants of metabolic health, will be modified to a differential extent in those who are on GLP1-RAs vs those where GLP1-RAs are discontinued. Understanding the role these medications play in not only clinical outcomes after metabolic surgery but potential metabolic mechanisms by which surgery improves patient's metabolic health could help people with obesity and type 2 diabetes make informed decisions about their treatment options as well as advise providers on the continuation of these medications in the perioperative and postoperative period. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/31/2025

Locations: University of Missouri Hospital, Columbia, Missouri

Conditions: Morbid Obesity, Metabolic Syndrome, Diabetes Mellitus, Hypertension, Obstructive Sleep Apnea of Adult

Register for Updates

Learn More ›

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

NCT03374215

Recruiting

Background: The adrenal gland makes the hormone aldosterone. This helps regulate blood pressure. An adrenal gland tumor that makes too much aldosterone can cause high blood pressure and low potassium. The cause of these tumors is unknown, but sometimes they are inherited. Objective: To study the genes that may cause primary aldosteronism in Black individuals. Eligibility: People ages 18-70 who: Are Black, African American, or of Caribbean descent And have difficult to control blood pressu... Read More

Background: The adrenal gland makes the hormone aldosterone. This helps regulate blood pressure. An adrenal gland tumor that makes too much aldosterone can cause high blood pressure and low potassium. The cause of these tumors is unknown, but sometimes they are inherited. Objective: To study the genes that may cause primary aldosteronism in Black individuals. Eligibility: People ages 18-70 who: Are Black, African American, or of Caribbean descent And have difficult to control blood pressure or primary aldosteronism Relatives of people with primary aldosteronism Design: Participants who are relatives of people with primary aldosteronism will have only 1 visit, with medical history and blood tests. Participants with primary aldosteronism or difficult to control blood pressure (suspected to possibly have primary aldosteronism) will be screened with a 1-2 hour visit. If they qualify, they will return for a hospital stay for 7-10 days. Tests may include: Medical history Physical exam Blood tests: Participants will have a small tube (IV catheter) inserted in a vein in the arm. They may drink a glucose-containing liquid or get a salt solution. If medically indicated, they may have invasive blood tests with a separate consent. Urine tests: Some require a high-salt diet for 3 days. Heart tests Scans: Participants lie in a machine that takes pictures of the body. A dye may be injected through a vein. Small hair sample taken from near the scalp. Kidney ultrasound Bone density scan: Participants lie on a table while a camera passes over the body. If the doctors feel it is medically necessary, they will offer participants treatment depending on their results. These treatments may cure the patient of their disease and may include: 1. Having one adrenal gland removed by the Endocrine surgeon under anesthesia. Patients will have follow-up visits 2-4 weeks after surgery. 2. Taking drugs to block the effects of aldosterone Participants may return about 1 year later to repeat testing. Read Less

Gender:

ALL

Ages:

Between 7 years and 70 years

Trial Updated:

07/31/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Adrenal Gland Neoplasm, Hypertension, Bone Diseases, Metabolic, Cardiovascular Disease, Hyperinsulinemia

Register for Updates

Learn More ›

Sleep Restriction and Parental History of Hypertension

NCT06482814

Recruiting

The purpose of this study is to research the effects of partial sleep deprivation (sleep restriction) in a group of individuals whose parents have high blood pressure compared to a group of individuals whose parents have normal blood pressure.

Gender:

ALL

Ages:

Between 18 years and 35 years

Trial Updated:

07/30/2025

Locations: Mayo Clinic in Rochester, Rochester, Minnesota

Conditions: Hypertension

Register for Updates

Learn More ›

WEAVE NM: Heart Health and Nutrition for Life

NCT07074145

Recruiting

WEAVE NM (Wide Engagement for Assessing Vaccine Equity in New Mexico) is a community-based research initiative working to improve health outcomes in underserved populations, with a current focus on hypertension and food justice. The project centers on the lived experiences of Native American, African American, Hispanic/Latino, and Asian American residents in Albuquerque's International District and South Valley. With guidance from community voices and ongoing collaboration with local organizatio... Read More

WEAVE NM (Wide Engagement for Assessing Vaccine Equity in New Mexico) is a community-based research initiative working to improve health outcomes in underserved populations, with a current focus on hypertension and food justice. The project centers on the lived experiences of Native American, African American, Hispanic/Latino, and Asian American residents in Albuquerque's International District and South Valley. With guidance from community voices and ongoing collaboration with local organizations, health providers, and residents, the initiative integrates cultural values, public policy, and social realities into solutions that promote equity and wellness. As part of this work, a clinical trial is being conducted through First Nations Community HealthSource (FNCH) to evaluate a culturally tailored blood pressure intervention called Heart Health and Nutrition for Life (HHNL). The trial includes patients who receive standard hypertension care and blood pressure self-monitoring, with one group also participating in a community health worker-led educational program in their first six months of study enrollment. This curriculum addresses healthy eating, physical activity, medication adherence, stress reduction, and avoidance of alcohol and tobacco, all delivered with cultural sensitivity and community insight. After six months, the groups switch roles, allowing all participants to receive the education component. Participants' progress is measured over a 12-month period by tracking changes in blood pressure, cholesterol, weight, blood sugar (HbA1c), and emotional well-being. The aim is to determine whether this community-supported approach improves outcomes more effectively than standard care alone with blood pressure self-monitoring. This study represents a broader effort to create long-term, community-rooted solutions to chronic health issues by addressing the social and environmental factors that influence well-being. For individuals living in the International District or South Valley, this project offers the opportunity to take part in research that respects cultural identity and prioritizes real-world impact on health. Interested patients and families can contact their provider at FNCH to learn more about participation. Read Less

Gender:

ALL

Ages:

Between 18 years and 84 years

Trial Updated:

07/28/2025

Locations: First Nations Community HealthSource, Albuquerque, New Mexico

Conditions: Hypertension

Register for Updates

Learn More ›

Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US

NCT05129345

Recruiting

This study has 3 aims. Aim 1: Identify social determinants of cardiometabolic health and determine facilitators and modifiable barriers in achieving treatment goals. Aim 2: Assess PLWH knowledge, skills, and confidence for self-management of cardiometabolic disorders. Aim 3: Tailor a self-management support and education intervention with stakeholder input to address barriers to achieving treatment goals for cardiometabolic disorders in PLWH at the study sites.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/23/2025

Locations: Duke University - Charlotte Study Sites, Charlotte, North Carolina +1 locations

Conditions: Hypertension, Dyslipidemias, Type 2 Diabetes, HIV-1-infection

Register for Updates

Learn More ›

Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women

NCT04439370

Recruiting

This is a cross-sectional study in which the investigators will determine the impact of premature/early menopause on MSNA, BP and baroreflex sensitivity in younger (≤49 yr old) and older (≥50 yr old) women. Specifically, aim one will determine mechanisms driving autonomic dysregulation of BP in premature and early menopausal women and aim two will determine mechanisms driving autonomic dysregulation of BP in older menopausal women. The study design outlined below will permit testing of aim one a... Read More

Gender:

FEMALE

Ages:

Between 35 years and 70 years

Trial Updated:

07/22/2025

Locations: University of Minnesota, Minneapolis, Minnesota

Conditions: Hypertension, Menopause, Premature, Menopause, Blood Pressure

Register for Updates

Learn More ›

A Study of LY3971297 in Healthy Participants

NCT06148272

Recruiting

The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 7-part study. The study duration will be approximately 60 days for Parts A and F, and approximately 90 days for Parts B, C, D, E, and G.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/22/2025

Locations: CenExel ACT, Anaheim, California +5 locations

Conditions: Healthy, Obesity, Hypertension

Register for Updates

Learn More ›

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

NCT06948422

Recruiting

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/22/2025

Locations: Elite Clinical Studies, LLC, Phoenix, Arizona +100 locations

Elite Clinical Studies, LLC, Phoenix, Arizona

Valley Clinical Trials, Inc., Covina, California

Valley Clinical Trials, Inc., Northridge, California

Chase Medical Research, LLC, Waterbury, Connecticut

Excel Medical Clinical Trials, Boca Raton, Florida

Care Access - Brandon, Brandon, Florida

Northeast Research Institute - Downtown Office, Jacksonville, Florida

Peace River Cardiovascular Center, Port Charlotte, Florida

Care Access - Sun City Center - Cypress Village Boulevard, Sun City Center, Florida

East-West Medical Research Institute, Honolulu, Hawaii

Sinai Hospital Of Baltimore, Baltimore, Maryland

Ascension Saint Agnes Heart Care, Baltimore, Maryland

Lucida Clinical Trials, New Bedford, Massachusetts

Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy, Michigan

StudyMetrix Research, Saint Peters, Missouri

Excel Clinical Research, LLC, Las Vegas, Nevada

Palm Research Center Sunset, Las Vegas, Nevada

Rochester Clinical Research, LLC, Rochester, New York

Remington-Davis, Inc, Columbus, Ohio

PriMED Clinical Research, Dayton, Ohio

Advanced Research Institute - Tigard, Tigard, Oregon

Care Access - Mauldin, Mauldin, South Carolina

Dallas Heart and Vascular Consultants, PA, Duncanville, Texas

Texas Institute of Cardiology, PA, McKinney, Texas

North Hills Family Medicine/North Hills Medical Research, North Richland Hills, Texas

Advanced Research Institute, Ogden, Utah

Carient Heart & Vascular - Manassas, Manassas, Virginia

Health Research of Hampton Roads, Inc., Newport News, Virginia

National Clinical Research, Inc, Richmond, Virginia

Eastside Research Associates, Redmond, Washington

Santa Maria de la Salud Centro Medico, San Isidro, Buenos Aires

CIPREC, Buenos Aires, Ciudad Autónoma De Buenos Aires

Centro de Investigaciones Clínicas Baigorria, Granadero Baigorria, Santa Fe

INECO Neurociencias Oroño, Rosario, Santa Fe

Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica, Rosario, Santa Fe

Instituto Médico Especializado (IME), Buenos Aires, Not set

CIPREC, Buenos Aires, Not set

CEMEDIC, Buenos Aires, Not set

Instituto de Investigaciones Clínicas Córdoba, Córdoba, Not set

Beijing Pinggu District Hospital, Beijing, Beijing

The Second Affiliated Hospital of Chongqing Medical University - Yuzhong Campus, Chongqing, Chongqing

The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi, Henan

Changde First People's Hospital, Changde, Hunan

Wuxi People's Hospital, Wuxi, Jiangsu

China-Japan Union Hospital, Changchun, Jilin

Siping Central People's Hospital, Siping, Jilin

Shaanxi provincial people's hospital, Xian, Shaanxi

Jinan Central Hospital, Jinan, Shandong

Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai

Sichuan Provincial People's Hospital, Chengdu, Sichuan

Lishui Central Hospital, Lishui City, Zhejiang

Top Moravia Health, Brno, Brno-město

Ordinace Rihackovi, s.r.o., Brno, Brno-město

CTC Hodonin s.r.o., Hodonin, Hodonín

CCR Ostrava s.r.o, Ostrava, Moravskoslezský Kraj

Diahelp s.r.o, Pardubice V, Pardubice

Angiocentrum Komorany, Prague, Praha 12

MUDr. Sarka Drinkova, Ledec nad Sazavou, Vysočina

Clinoxus, Praha 4, Not set

Praglandia s.r.o, Praha 5, Not set

Kardiologische Praxis Dr. med. univ. Wolfgang Jungmair, Bad Homburg, Hessen

Medizentrum Essen Borbeck, Essen, Nordrhein-Westfalen

Zentrum fur klinische Forschung - Köln, Köln, Nordrhein-Westfalen

Hausärztlich-Kardiologisches MVZ am Felsenkeller GmbH/Zentrum für klinische Studien, Dresden, Sachsen

Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Sachsen

AmBeNet GmbH, Leipzig, Sachsen

Familienmedizinisches Zentrum Radowsky, Leipzig, Sachsen

RED-Institut GmbH, Oldenburg, Schleswig-Holstein

emovis GmbH, Berlin, Not set

Athens Medical Center - Psychikon branch, Athens, Attikí (Region)

General Hospital of Athens "G. Gennimatas", Athens, Attikí

University Hospital of Ioannina, Ioannina, Ioánnina

G. Gennimatas General Hospital of Thessaloniki, Thessaloniki, Thessaloníki

AHEPA University General Hospital of Thessaloniki, Thessaloniki, Thessaloníki

Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Thessaloníki

G.B. Pant Institute of Postgraduate Medical Education & Research, New Delhi, Delhi

Life Care Hospital and Research Centre, Bangalore, Karnataka

Ashirwad Hospital and Research Centre, Ulhasnagar, Maharashtra

All India Institute of Medical Sciences, Bhubaneswar, Odisha

Mikannohana Clinic, Diabetes, Endocrinology and Metabolism, Matsuyama, Ehime

Takai Internal Medicine Clinic, Kamakura-shi, Kanagawa

Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic, Yamato-shi, Kanagawa

Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo

Fukuwa Clinic, Chuo-ku, Tokyo

NZOZ Regionalna Poradnia Diabetologiczna, Wroclaw, Dolnośląskie

Centrum Medyczne "Hipokrates" S.C. Elżbieta I Grzegorz Grześk, Bydgoszcz, Kujawsko-pomorskie

NZOZ Centrum Medyczne KERmed, Bydgoszcz, Kujawsko-pomorskie

Balsam Medica, Warsaw, Mazowieckie

Private Practice - Dr. Robert Witek, Tarnów, Małopolskie

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu, Przemysl, Podkarpackie

Uniwersytecki Szpital Kliniczny w Białymstoku, Białystok, Podlaskie

IRMED, Piotrkow Trybunalski, Łódzkie

Dorado Medical Complex, Dorado, Not set

Puerto Rico Medical Research, Ponce, Not set

CHUAC-Complejo Hospitalario Universitario A Coruña, A Coruña, A Coruña [La Coruña]

Hospital San Rafael - La Coruña, La Coruña, A Coruña [La Coruña]

Hospital Quiron Infanta Luisa, Sevilla, Andalucía

EAP Sardenya, Barcelona, Barcelona [Barcelona]

EAP Osona Sud - Alt Congost S.L.P, Centelles, Barcelona [Barcelona]

Complejo Asistencial Universitario de León - Hospital de León, León, Castilla Y León

Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE), Sevilla, Not set

Conditions: Hypertension

Register for Updates

Learn More ›

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

NCT06948435

Recruiting

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.